Burkitt's lymphoma treatment cost in Israel varies significantly based on the protocol intensity and necessary interventions. Primary therapeutic options such as chemotherapy range from $2,400 to $5,500, while a bone marrow transplantation runs from $135,000 to $240,000. Total expenses depend on the disease stage and the need for advanced therapies like CAR T-cell protocols. Patients often realize 30–50% savings compared to the US. Top treatment centers are located in Tel Aviv, Jerusalem, and Ramat Gan.
Typical Burkitt's Lymphoma Treatment Costs in Israel
Bookimed Expert Insight: High-intensity chemotherapy is the standard for Burkitt's lymphoma. Sourasky Medical Center (Ichilov) reports a 90% success rate for oncology treatments. Pediatric patients should prioritize centers like Hadassah, where Professor Polina Stepensky has performed over 3,500 transplants. For refractory cases, Sheba Medical Center offers globally ranked CAR T-cell programs. These multidisciplinary centers provide better value by coordinating complex hematological care in one facility.
| Israel | Turkey | Austria | |
| Chemotherapy for breast cancer | from $22,500 | from $1,200 | from $15,000 |
| Chemotherapy | from $2,400 | from $2,700 | from $2,500 |
| Bone marrow transplantation | from $135,000 | from $36,000 | from $140,000 |
| Autologous bone marrow transplantation | from $58,000 | from $31,500 | from $50,000 |
| Allogenic bone marrow transplantation from an unrelated donor | from $135,000 | from $80,000 | from $180,000 |
Dr. Ram Ron treats Burkitt's lymphoma at the Sourasky Medical Center (Ichilov), one of Israel's largest and most advanced hospitals.
Performed several hundred stem cell transplants – a key treatment for aggressive lymphomas. Dr. Ram is a triple board-certified hematologist-oncologist based at Ichilov Hospital.
Head of Pediatric Oncohematology at Dana Dwek Children’s Hospital – Dr. El Hasid specializes in bone marrow and umbilical blood transplants for children.
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.